GM-CSF in Patients With Pulmonary Alveolar Proteinosis

Pulmonary Alveolar Proteinosis Clinical Trial

Official title: Trial of GM-CSF for Alveolar Proteinosis

Status Terminated

Clinical Trial Summary

This is a study to determine the efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered subcutaneously to patients with pulmonary alveolar proteinosis (PAP).

Clinical Trial Description

PAP is a rare lung disease characterized by accumulation of surfactant phospholipids and proteins within the lungs. There is no specific pharmacologic therapy for PAP and the current practice of lung lavage under general anesthesia is invasive and has limitations. Although it is unknown if the anti GM-CSF antibody is related to the disease pathogenesis, observations suggest a role for GM-CSF in lung homeostasis as well as in the pathogenesis of PAP.

Patients will receive subcutaneous GM-CSF or placebo once a day and will be followed on an outpatient basis at 2 weeks, and 1, 2, 3, 4, 5 and 6 months after initiation of therapy. Clinical response will determine dosing schedule and will be evaluated by symptom scores, gas exchange data, and chest radiographs.

Completion date provided represents the completion date of the grant per OOPD records ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Pulmonary Alveolar Proteinosis

• NCT number: NCT00030056
• Study type: Interventional
• Source: FDA Office of Orphan Products Development
• Status: Terminated
• Phase: Phase 2
• Start date: September 2001
• Completion date: December 2005